BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34053791)

  • 1. Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M
    Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
    Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
    Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Afsar A; Mallya A; Mohammed AAG; Anand S; Diomande VKF; Maufras du Châtellier G; Ather F
    Vaccine; 2023 Apr; 41 Suppl 1():A79-A84. PubMed ID: 36642630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A circulating vaccine-derived poliovirus type 2 outbreak in a chronic conflict setting: a descriptive epidemiological study in South Sudan - 2020 to 2021.
    Tegegne AA; Anyuon AN; Legge GA; Ferede MA; Isaac Z; Laku KA; Biadgilign S; Kilo OTD; Ndenzako F; Modjirom N; Olu OO; Maleghemi S
    BMC Infect Dis; 2023 Nov; 23(1):816. PubMed ID: 37990165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
    Jorba J; Diop OM; Iber J; Henderson E; Sutter RW; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2017 Nov; 66(43):1185-1191. PubMed ID: 29095803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
    Macklin GR; Goel AK; Mach O; Tallis G; Ahmed JA; O'Reilly KM; Grassly NC; Diop OM
    Vaccine; 2023 Apr; 41 Suppl 1():A19-A24. PubMed ID: 36008232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities.
    Khetsuriani N; Perehinets I; Nitzan D; Popovic D; Moran T; Allahverdiyeva V; Huseynov S; Gavrilin E; Slobodianyk L; Izhyk O; Sukhodolska A; Hegazi S; Bulavinova K; Platov S; O'Connor P
    Vaccine; 2017 Aug; 35(36):4769-4776. PubMed ID: 28528761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epidemiological analysis of Acute Flaccid Paralysis (AFP) surveillance in Kenya, 2016 to 2018.
    Tesfaye B; Sowe A; Kisangau N; Ogange J; Ntoburi S; Nekar I; Muitherero C; Camara Y; Gathenji C; Langat D; Sergon K; Limo H; Nzunza R; Kiptoon S; Kareko D; Onuekwusi I
    BMC Infect Dis; 2020 Aug; 20(1):611. PubMed ID: 32811467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
    Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA
    BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
    Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.